Society for Immunotherapy of Cancer (SITC)

The hematologist/oncologist from Mayo Clinic discussed the BASECAMP study and how it will inform future studies assessing Tmod technology.

CRISPR Therapeutics presented positive data on 2 preclinical programs at the 2021 SITC meeting.

The NK cell therapy is also being evaluated in a phase 1 study for acute myeloid leukemia.

Overall survival was 72% at 12 months but dropped to 54% at 14.6 months.

A single administration of LN-145 monotherapy resulted in an overall response rate of 21.4% in patients with immunotherapy pretreated metastatic non–small cell lung cancer.

The first in-human study of CAR macrophages has dosed 2 participants so far.

The BASECAMP-1 study is identifying patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) for future use of these therapies.

Three patients dosed had tumors shrinkages of 18%, 21%, and 27%.

Data from the IMA203 trial were presented at the SITC 2021 annual meeting.